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Background: Previous studies using the electroencephalogram (EEG) technique
pointed out that ketamine decreases the amplitude of cortical electrophysiological signal
during cognitive tasks, although its effects on the perception and emotional-valence
judgment of stimuli are still unknown.
Objective: We evaluated the effect of S-ketamine on affective dimension of pain using
EEG and behavioral measures. The hypothesis was that S-ketamine would be more
effective than placebo, both within and between groups, to attenuate the EEG signal
elicited by target and non-target words.
Methods: This double-blind parallel placebo-controlled study enrolled 24 healthy
male volunteers between 19 and 40 years old. They were randomized to receive
intravenous S-ketamine (n = 12) at a plasmatic concentration of 60 ng/ml or placebo
(n = 12). Participants completed a computerized oddball paradigm containing written
words semantically related to pain (targets), and non-pain related words (standard).
The volunteers had to classify the words either as “positive,” “negative” or “neutral”
(emotional valence judgment). The paradigm consisted in 6 blocks of 50 words each
with a fixed 4:1 target/non-target rate presented in a single run. Infusion started during
the interval between the 3rd and 4th blocks, for both groups. EEG signal was registered
using four channels (Fz, Pz, Pz, and Oz, according to the 10–20 EEG system) with
a linked-earlobe reference. The area under the curve (AUC) of the N200 (interval of
100–200 ms) and P300 (300–500 ms) components of event-related potentials (ERPs)
was measured for each channel.
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Results: S-ketamine produced substantial difference (delta) in the AUC of grand
average ERP components N200 (P = 0.05) and P300 (P = 0.02) at Pz during infusion
period when compared to placebo infusion for both targets and non-targets. S-ketamine
was also associated with a decrease in the amount of pain-related words judged as
negative from before to after infusion [mean = 0.83 (SD = 0.09) vs. mean = 0.73
(SD = 0.11), respectively; P = 0.04].
Conclusion: Our findings suggest that S-ketamine actively changed the semantic
processing of written words. There was an increase in electrophysiological response for
pain-related stimuli and a decrease for standard stimuli, as evidenced by the increased
delta of AUCs. Behaviorally, S-ketamine seems to have produced an emotional and
discrimination blunting effect for pain-related words.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT03915938.
Keywords: ERPs, ketamine, P300, pain, oddball
INTRODUCTION
Ketamine is a dissociative anesthetic with N-methyl-D-aspartate
(NMDA) glutamate receptor antagonism, which was synthesized
for the first time in 1960 and approved by FDA to induction
of general anesthesia in 1970 (Domino, 2010). Ketamine has
hallucinogenic potential, differing from other intravenous and
inhaled anesthetics at the molecular, neural, and behavioral levels.
Recently, the use of low-dosage (subanesthetic) ketamine has
been under investigation as an adjuvant therapy to treat both
postoperative acute and chronic pain (Noppers et al., 2010;
Michelet et al., 2018). In addition, it is also considered as an
option in the treatment of psychiatric disorders, as refractory
major depression (Mathew et al., 2012; Zarate et al., 2012).
Although ketamine is classified as an NMDA receptor
antagonist, ketamine was found to also interact with other
receptors and ion channels, including serotonin (Kapur and
Seeman, 2002), opioid (Gupta et al., 2011) and dopamine
(Seeman and Guan, 2008) receptors, as well as possibly enhancing
glutamate AMPA receptor’s density and function (Aleksandrova
et al., 2017). It has been postulated that the NMDAR antagonists,
such as ketamine, decrease GABAergic interneuron function
by NDMA receptor blocking in the prefrontal cortex and lead
to increased excitation of pyramidal neurons (Kadriu et al.,
2019). Also, another study showed that the ketamine’s effect
increased the activity of high-affinity extra synaptic GABAA
receptors in the hippocampus and cortex (Wang et al., 2017).
In healthy subjects, it produces transient and reversible clinical
and electrophysiological changes that emulate the ones found in
schizophrenic disorder and could lead to further understanding
of abnormal brain functioning (Krystal et al., 1994; Adler et al.,
1998; de la Salle et al., 2016; Friston et al., 2016). Many
neuroimaging studies (Holcomb et al., 2001; Rogers et al.,
2004; Deakin et al., 2008; Niesters et al., 2012) addressed
ketamine’s actions on the brain, but it has been difficult to
interpret ketamine’s cortical effects based on these surrogate
outcome measures. It has been shown that ketamine, despite
being traditionally classified as a NMDA receptor antagonist,
could lead to an increase of glutamate release in specific
brain areas (Holcomb et al., 2001; Deakin et al., 2008; Rosch
et al., 2019). In this context, electroencephalographic studies
could be useful to investigate correlates of cognitive effects on
cortical electrophysiology.
Event-related potentials (ERPs) reflect stimuli processing in
real time. Using this technique, studies found that ketamine
consistently decreases P300 amplitude in different oddball tasks
using both visual and auditory stimuli (Oranje et al., 2009;
Watson et al., 2009; Musso et al., 2011). These ERP changes are
associated with decreased attention levels, as well as an impaired
capacity to differentiate sensorial stimuli (Musso et al., 2011).
When used as analgesic, a subanesthetic dose of ketamine is
very effective reducing pain unpleasantness. However, perceived
pain intensity does not seem to be greatly affected (Sigtermans
et al., 2009). This fact can be explained by the multifactorial
vulnerability of pain perception, including affective and sensorial
modulation. Hence, the analgesic effect of ketamine might be
influenced by a decreased affective discrimination of sensorial
information (Sprenger et al., 2006; Oertel et al., 2009). This
concept has support on neuroimaging studies describing changes
in the activity of specific brain areas that are related to affective
component of pain, as the anterior cingulate cortex (ACC).
This effect suggests that the euphoria provoked by ketamine
actively interacts with the emotional aspect of pain more critically
than with the pain sensory-discriminative aspects (Sprenger
et al., 2006). Ketamine has multiple effects including memory
loss, sedation, hypnosis, analgesia, and in the last decade, we
found robust evidences of subanesthetic doses impact in the
treatment of patients with major depression who do not respond
to conventional antidepressant drugs (Andrade, 2017). Although
several properties of ketamine have been demonstrated across
50 years of clinical use, new insights of its impact in the
processing of the affective dimension are needed.
Thus, this study was designed to evaluate the effect of
S-ketamine on the affective dimension of pain. We used
an oddball experimental paradigm containing written words
semantically related to pain (target) and non-pain related words
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(standard). The volunteers classified the words as follows,
according to the semantic valence: “positive,” “negative” or
“neutral.” We tested the hypothesis that the S-ketamine would
be more efficient than the placebo, within and between groups,
to decrease the area under de curve (AUC) of the grand




The protocol was approved by Institutional Review Board (IRB)
at the Hospital de Clínicas de Porto Alegre (HCPA) (IRB no.
15-0019) in accord to the Declaration of Helsinki. Volunteers
provided oral and written informed consent before participating
in this randomized, double-blind, placebo-controlled trial.
Database of this study will be available on request to the
corresponding author. Recruitment took place from January
2017 to July 2018.
Subject Characteristics and Study
Inclusion and Exclusion Criteria
We recruited non-smoker healthy volunteers by advertisement
postings at universities, on the internet and in public places
of the Porto Alegre area. They were screened for eligibility by
phone and were considered eligible to participate if they were
male, right-handed, fluent in Brazilian Portuguese, age range 19
to 40 years old. Volunteers answered a structured questionnaire
that assessed current acute or chronic pain conditions, use of
analgesics in the past week, rheumatologic disease, clinically
significant or unstable medical or psychiatric disorder, history of
alcohol or substance abuse in the past 6 months, neuropsychiatric
comorbidity, use of psychotropic drugs and they could not
have prior experience with S-ketamine. Subjects had normal or
corrected-to-normal vision. Individuals with Beck Depression
Inventory (BDI) (Warmenhoven et al., 2012) scores higher
than 13 were excluded (Beck and Koenig, 1996). We only
included male subjects in order to avoid the influence of cyclical
fluctuation of gonadal steroids during menstrual cycle on pain
processing and in cortical excitability parameters (Stefani et al.,
2012). Also, previous data suggest that S-ketamine displays sex
differences in its pharmacokinetics (Sigtermans et al., 2009).
Twenty-four healthy subjects were randomized. Three
volunteers (one of S-ketamine group and two of group placebo)
were excluded in some ERP analysis due to excessive artifacts
and bad quality of signal, hence, 22 subjects were included in the
analysis of electroencephalographic data of Fz and Cz, while 21
subjects were included in analysis of Cz and Oz. Demographic
and psychological characteristics of the subjects were comparable
and are shown in Table 1. BDI-II scores showed a statistically
significant difference between groups but were very low in both
groups. Side effects were observed in 15 subjects (6 in group
placebo and 9 in group S-ketamine), including somnolence,
subjective lentification and light headache. One subject (S-
ketamine group) experienced nausea requiring antiemetic
treatment after completion of protocol.
TABLE 1 | Baseline characteristics of the sample.
S-ketamine Placebo
(n = 12) (n = 12)
Mean (SD) Mean (SD) P-value
Age (years) 26.0 (3.6) 28.5 (3.3) 0.29
Weight (Kg) 73.3 (10.7) 84.1 (11.1) 0.17
Height (cm) 176.3 (6.3) 181.0 (7.5) 0.29
Education (years) 16.9 (1.2) 18.3 (1.7) 0.86
Beck depression inventory (BDI-II) 1.2 (1.0) 3.0 (1.1) 0.01
Trait anxiety (STAI-T) 16.4 (2.5) 18.3 (2.5) 0.29
State anxiety (STAI-E) 20.6 (3.2) 21.3 (3.5) 0.69
Concentrated attention test 95.0 (36.3) 81.3 (32.6) 0.49
Data are presented as mean and standard deviation (n = 24).
Sample Size
The number of subjects was determined according to parameters
of a previous study (Oranje et al., 2009). A priori estimate
indicated in a superiority test from a parallel design, a sample
size of 20 subjects divided into two groups with a 1:1 ratio, to
test for difference between intervention groups of 1.24 mV on
mean P300 amplitudes for lead Pz, considering an effect size of
0.54, to achieve 80% power at a 5% significance. Considering
possible losses, sample size was increased in 20% (24 subjects).
The estimative was determined using the Power Analysis and
Sample Size Software PASS version 13 (NCSS Statistical Software,
Kaysville, Utah).
Randomization
The randomization was generated by a computer (Research
Randomizer R©) with a fixed block size of four. Twenty-four
subjects were randomly allocated to receive an intravenous
infusion of a subanesthetic dose of S-Ketamine or placebo
(normal saline). Before the recruitment phase, opaque envelopes
containing the protocol materials were prepared, each one sealed
and numbered sequentially. The envelopes were opened by
the nurse who prepared the medications only after volunteers
provided written informed consent.
Blinding
Experimenters and subjects were blind to the drug condition.
An inherent limitation to nearly all ketamine experiment designs
is that the extent to which researchers are blinded is limited
by the obvious subjective effects of ketamine such as perceptual
aberrations, the sense of derealization and the feeling of loss
of control over thought processes. We sought to remedy this
by previously diluted drug solutions and having separate study
personnel record and process the EEG data.
Interventions
An intravenous 22G cannula was placed in the antecubital
face of the left arm. EEG recording and standard monitoring
(electrocardiogram, pulse oximetry and non-invasive blood
pressure) were initiated. The semantic written word oddball
task was started after a brief 10-word training period.
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FIGURE 1 | Procedures. (A) Representation of subject positioning, monitoring and generation of ERPs. Twenty-four healthy men were randomized to receive an
infusion of S-ketamine or placebo. (B) Sequence of procedures. All participants completed six runs, grouped into three blocks. A block was made up of a single run
consisting in 50 words (10 target, 40 neutral) interrupted by a 30-seconds resting trace. After completion of the first 3 blocks, infusion was initiated (S-ketamine or
placebo), and participants rested for 3 min. Following the third block, euphoria and sedation ratings were scored in each block intervals (∗). (C) Semantic oddball
paradigm. Each trial began with a fixation cross in the center of a black screen, after which the stimuli were presented for 1000 ms each. Participants were instructed
to classify each presented word as “positive,” “negative,” or “neutral” according to their subjective interpretation. The participants pressed the “left arrow” key if the
word was negative, “up arrow” if neutral or “right arrow” if positive. Interstimulus interval was randomized in 1500 ± 500 ms during which the fixation cross appeared
on the screen.
Paradigm consisted of 6 blocks of 50 words with a fixed 4:1
target/non-target relation presented in a single run (Figure 1).
Target words were somatosensory pain-related derived from
the McGill Pain Questionnaire version validated to Brazilian
Portuguese (Pimenta and Teixeiro, 1996) and standard stimuli
were non-pain related words selected from a previously published
word list (Stein and de Azevedo Gomes, 2009) and balanced
with target words according shape, number of syllables and
concreteness. Stimuli were presented in a computer screen with
a duration of 1000 ms and a pseudorandomized inter-stimulus
interval of 1500 (±500) ms. After each stimulus, volunteers
were instructed to rate each presented word according to its
emotional valence as positive, negative or neutral, by pressing
a correspondent key in the computer keyboard (using their
right hand) (Figure 1). Over the task time, a total of 300
words were presented.
Group S-ketamine received a target controlled infusion of
ketamine to obtain a plasmatic target of 60 ng/ml according to
Domino’s model (Corssen and Domino, 1966). S-ketamine doses
were selected to have mild-to-moderate psychogenic and sedating
effects based on previous studies (Krystal et al., 2003; Knott et al.,
2011; Musso et al., 2011) and were well tolerated. Infusion started
during the interval between the 3rd and 4th blocks for both
groups. According to the pharmacokinetic model, drug reached
steady state along the 4th block.
Instruments and Assessments
Upon arriving, participants were seated in a dimly lit,
sound-attenuated, testing room, and answered to self-
rating basal questionnaires to determine levels of anxiety
(State-Trait Anxiety Inventory – STAI adapted to Brazilian
Portuguese (Kaipper et al., 2010), depressive symptoms
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[Beck Depression Inventory-II (Wang and Gorenstein, 2013)]
and attention (AC test). Demographic data were gathered using
a standardized questionnaire.
Outcomes
Primary outcomes consisted of the area-under-the-curve (AUC)
of the P300 ERP component (considering a window of
300–500 ms post-stimulus) for parietal electrophysiological
signal (Pz) and AUC of the N200 component (window
100–200 ms post-stimulus). Secondary outcomes were the mean
difference (delta) between target and non-target peak amplitudes
and latencies for both P300 and N200 components according to
each electrode (Fz, Cz, Pz, and Oz).
ERPs
EEG data were acquired using sintered electrodes from midline
scalp sites (Fz, Cz, Pz, and Oz) using a linked-earlobe reference
(frontal Fp1, Fp2 sites were also monitored for eye blinking
artifacts). Electrodes were connected to a digital data-acquisition
system, ENOBIO 20 (Neuroelectrics R©, Barcelona), which sent
signals via Bluetooth interface to a laptop equipped with the NIC
2.0 software (Neuroelectrics R©, Barcelona). The data were digitized
at 1000 Hz with a gain of 500, and were bandpass filtered between
0.1 and 100 Hz during acquisition. Electrode impedances did not
exceed 10 k. Data were low-pass filtered at 30 Hz offline prior
to epoching. ERP epochs were obtained from −100 to 1000 ms
following stimulus presentation. An automated ocular correction
routine (Gratton et al., 1983) was applied to remove blink an
eye-movement artifacts. Epochs were baseline corrected using a
−100 to 0 ms interval. Any corrected epochs containing EEG
amplitudes exceeding ±75 µV were excluded from analysis.
The AUCs were chosen over average peak amplitudes and
latencies as they give a better component representation as
previously described (Bandt et al., 2009). Based on inspection of
the grand-average waveforms, the N200 component was defined
as the negative-going peak in a latency window of 150 to
250 ms following target stimulus onset. The P300 component was
defined as the largest positive-going peak immediately following
the P200 component. A manual routine was used to measure
the peak amplitudes (relative to the pre-stimulus baseline) and
latencies. Two evaluators independently identified ERP peaks
using the criteria described above. When necessary, divergence
on the identified peaks were resolved by discussion with a third
study author. ERP averages were created for each stimulus type
(standards and targets) X drug type (placebo, S-ketamine) X
time (pre- and post-infusion) X electrode (Fz, Cz, Pz and Oz)
combination. Only data of 5th and 6th blocks were considered
for post-infusion values to ensure constant S-ketamine plasmatic
levels (steady state).
Behavioral Measures
Behavioral performance measures included the percentage of
valence ratings (positive, negative or neutral) to target and
standard stimuli and the mean response time (RT). We also
examined the visual analog scale (VAS) scores measuring the
psychogenic response (“euphoria” and “sedation”) and attention
levels as potential confounding covariates for ERP analyses.
The clinical assessment of sedation was determined using a
VAS ranging from zero (sleepiness) to 10 (completely awake).
To capture the overall euphoria levels during the infusion period,
we assessed the VAS score after each one of the six word blocks,
as presented in Figure 1.
Statistical Analysis
Continuous data were evaluated for normality using Shapiro-
Wilk test. ERP data were analyzed using repeated-measures
Analyses of Variance (ANOVA). The ERP data (AUC, peak
amplitudes and latencies) were analyzed considering time (basal
period or steady state) and group (S-ketamine or placebo) as
factor for each stimulus type and channel (Gelman and Hill,
2007). AUCs were calculated for ERPs elicited by target and
standard stimuli. The behavioral data averages were analyzed
with a paired t-test to compare the drug effect within groups,
and t-test for independent samples was used to compare drug
effects between subjects. All analyses were performed with two-
tailed tests at the 5% significance level and were adjusted for
multiple comparisons using Bonferroni test. Due to the excessive
number of outcomes, some of our results should be considered
exploratory and thus need to be replicated in confirmatory
trials. All analyses were performed with SPSS version 20.0 (SPSS,
Chicago, IL, United States).
RESULTS
Treatment Effects on ERPs
The results of grand average ERPs analysis in the placebo and
S-ketamine groups are presented in Figure 2A. A repeated
measure ANOVA showed an interaction between time and group
(F(1, 20) = 8.24, p < 0.01). In Pz derivation, the AUC of
delta grand average waves for target and non-target stimuli
were larger in group S-ketamine when compared to group
placebo at 100–200, 300–500, and 800–900 ms periods after
stimulus (Figure 2C). Also, was observed a larger difference
between pre and post-infusion N200 and P300 amplitudes in
S-ketamine group compared to placebo group (p = 0.05; p = 0.02,
respectively) (Table 2).
Treatment Effects on Behavioral
Measures
The reaction times and the word ratings related to the semantic
valence assessed using the oddball paradigm are presented in
Table 2. There was no statistically significant difference between
intervention groups (S-ketamine or placebo) neither in the
reaction times nor in word ratings as “positive,” “negative,”
or “neutral.”
However, when we analyze the effect of the intervention
within groups, comparing before and after S-ketamine infusion,
S-ketamine reduced the negative ratings of target words (pain-
related) while increasing classification as “neutral” with a trend
for a significant difference (P = 0.052). The S-ketamine’s effect
significantly decreased the valence rating of non-target words as
negative and positive at the expense of increased word-ratings
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FIGURE 2 | Continued
as neutral. In group placebo, we found no difference for the
valence attribution of target words. There was a significant
lower proportion of non-target words judged as negative and an
increase of those judged as neutral. We did not observe effects
of S-ketamine or placebo in attention scores. Additionally, there
were no statistically significant correlations between S-ketamine’s
effect and reaction time, euphoria and sedation ratings with
the P300 AUC (Table 2). Thus, it is improbable that these side
effects could introduce a bias in the ERP. Hence, they were not
considered in the analysis.
DISCUSSION
These results confirm our hypothesis that the S-ketamine’s effect
was more efficient than placebo to change the delta AUCs relative
to N200 and P300 components in the Pz derivation for targets
and non-targets ERPs components during infusion period when
compared to placebo infusion. And, the difference between grand
averaged N200 and P300 amplitudes for target stimuli were
statistically significant lower in the S-ketamine group compared
to the placebo group. Also, these results revealed that S-ketamine
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FIGURE 2 | Continued
infusion led to a significant decrease in the amount of pain-
related words judged as negative from before to after infusion.
These findings provide important data supporting the notion
that the sub-anesthetic S-ketamine dose reduce the mean of
the AUC measures related to ERPs. The AUC values can
be interpreted as a less biased index, because it directly
reflecting amplitudes of N200 (100–200 ms post-stimulus
window) and P300 (300–500 ms post-stimulus) components
(Bandt et al., 2009). The difference between ERPs elicited by
target and non-target words (delta) corresponds to changes in
cortical activation secondary to the different semantic contents
(i.e., pain or non-pain related) of the stimuli. The topographic
distribution of the changes that we found is consistent to the
semantic modulation of ERPs that is generally observed centered
at parietal electrodes (Binder and Desai, 2011).
These results showed an increase in delta AUC values in
the placebo group, while the S-ketamine leads to a decreased
delta AUC secondary to the decrease in stimuli discrimination
(Figure 2). According to what previous studies found, ERP
amplitudes increase following the presentation of pain-related
words (Dillmann et al., 2000) and negative emotional pictures
(Stancak and Fallon, 2013) to healthy subjects, which was
Frontiers in Neuroscience | www.frontiersin.org 7 September 2019 | Volume 13 | Article 959
fnins-13-00959 September 24, 2019 Time: 14:9 # 8
Schwertner et al. Ketamine’s Effect on Electrophysiological Activity
FIGURE 2 | Continued
suggested to be secondary to pre-activation of neural networks
subserving pain memory and pain processing. Hence, similar
effects can be involved in the S-ketamine effect on emotional
aspects related to pain and other psychological effects that
improve depressive symptoms (Andrade, 2017). This hypothesis
finds support in earlier studies in healthy subjects, which
found a decreased P300 amplitudes in the S-ketamine group
(Ahn et al., 2003; Watson et al., 2009; Knott et al., 2011;
Musso et al., 2011; Koychev et al., 2016) and auditory (Oranje
et al., 2009; Gunduz-Bruce et al., 2012; Mathalon et al., 2014)
stimulation, which is inferred to be consequence of reduced
capacity to discriminate targets from standard stimuli. Although
the mechanism underlying S-ketamine’s effect on the brain
circuits involving the pain processing (and on sensory, emotional,
cognitive and interoceptive processing) remains to be fully
established, several lines of evidence indicate that this involves
the mechanism that transposes its properties to inhibit NMDA
receptors. Such a mechanism of modifying the function of
NMDAR blockade on GABAergic interneurons is also associated
with an enhance of extra synaptic GABA-A receptor activity
Frontiers in Neuroscience | www.frontiersin.org 8 September 2019 | Volume 13 | Article 959
fnins-13-00959 September 24, 2019 Time: 14:9 # 9
Schwertner et al. Ketamine’s Effect on Electrophysiological Activity
FIGURE 2 | (A) Grand averaged P300 ERP waveforms of target and non-target words during placebo and S-ketamine infusions at Pz, Fz, Cz, and Oz. (B) Grand
averaged difference between pre and post infusion periods (delta) in group S-ketamine (blue) and placebo (black); Gray-shaded areas denote statistically significant
differences. (C) Comparison of delta AUCs between groups placebo and S-ketamine. Asterisk indicates statistical significance (∗p < 0.05).
(Wang et al., 2017), as well acetylcholine, dopamine and opioid
receptors (Bergman, 1999; Chen et al., 2009).
It was described that P300 amplitudes tend to decrease
over time when using visual stimuli (Hopstaken et al.,
2016), which can explain decreased delta AUC for 300–
500 ms period seen in group placebo (p < 0.01). Also,
when a sequence follows a repeating pattern, performance
typically improves (Jentzsch and Sommer, 2001; Russeler et al.,
2003), often without conscious awareness (Honda et al., 1998;
Schlaghecken and Eimer, 2000). According to literature, at
least in auditory stimulation, the prediction of the targets
leads to a decrease in P300 amplitudes (Jongsma et al., 2013),
which possibly account for the reduced AUC difference seen
in placebo, and this repetition effect is reduced by S-ketamine
(Rosch et al., 2019).
Our findings suggest that S-ketamine reduced the individual’s
ability to predict the occurrence of the negative pain-related
words, thus blocking the decrease in expectative-induced ERP
changes. In fact, our results are aligned with the literature,
which suggests that S-ketamine induces experiences of abnormal
perception and an impaired cognitive-emotional evaluation of
significance that mimic findings which are observed in patients
with schizophrenia (Jeon and Polich, 2003). In the clinical context
of emotional blunting, it has been suggested that there is a
shift in the relative contribution of brain regions subserving
cognitive and emotional processing (Krystal et al., 1994; Deakin
et al., 2008). Studies using fRMI (Abel et al., 2003; Sprenger
et al., 2006; Deakin et al., 2008) previously reported reduced
activity in limbic and visual brain regions involved in emotion
processing, and increased activity in dorsal regions of the
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TABLE 2 | Classification of words according to semantic valence using the oddball paradigm in the S-ketamine and placebo groups.
S-ketamine (n = 12) Placebo (n = 12)
Before infusion After infusion SMD P-value ∗ Before infusion After infusion SMD P-value∗
Response time (ms)
851.9 (395.4) 855.12 (420.4) – 0.942 826.6 (281.8) 902.05 (406.1) – 0.402
Sedation score
13.21 (18.0) 29.64 (22.4) – 0.295 18.21 (16.6) 19.64 (16.3) – 0.238
Euphoria rating
2.50 (2.3) 2.21 (2.5) – 0.413 3.29 (2.37) 3.07 (2.1) – 0.281
Pain-related words (Target-words)
Positive 0.01 (0.03) 0.03 (0.04) – 0.212 0.03 (0.03) 0.03 (0.03) – 0.681
Neutral 0.16 (0.07) 0.24 (0.10) 0.25 0.052 0.16 (0.07) 0.19 (0.07) – 0.417
Negative 0.83 (0.09) 0.73 (0.11) −0.09 0.041 0.81 (0.09) 0.78 (0.08) – 0.402
Non-pain-related words (Non-target words)
Positive 0.51 (0.06) 0.40 (0.15) −0.17 0.041 0.56 (0.05) 0.49 (0.16) – 0.356
Neutral 0.24 (0.07) 0.48 (0.16) 0.40 < 0.01 0.18 (0.08) 0.37 (0.17) 0.41 0.032
Negative 0.25 (0.02) 0.12 (0.03) −0.53 < 0.01 0.26 (0.04) 0.14 (0.03) −0.44 < 0.01
Data are presented as mean percentages and standard deviations (n = 24). Standardized difference means (SDM); the blank signal (–) indicates that the SDM was not
calculated; ∗P-value of comparisons within groups by paired t-test adjusted by Bonferroni test for multiple comparisons.
prefrontal cortex and cingulate gyrus, both associated with
cognitive processing and, putatively, with emotion regulation.
In these studies, the amygdala and fusiform gyrus activity
was abolished in response to fearful faces following ketamine
administration and a relative increase in the visual cortical
response to neutral stimuli was observed (Abel et al., 2003).
Also, the previously described pattern of increased activation
of the right dorsolateral prefrontal cortex (DLPFC) and the left
insula due to emotional content is abrogated exclusively for
negative stimuli (Scheidegger et al., 2016) and may help explain
ketamine’s effect on the loss of the affective component on pain-
related word interpretation (Niesters et al., 2012). These previous
findings suggest that S-ketamine-induced effect on limbic and
visual regions is associated with the emotional and discriminative
blunting seen in ketamine states (Krystal et al., 1994). Such an
interpretation is consistent with the present findings. In fact, we
found evidence that S-ketamine also induced changes in later
cognitive-evaluative processes, as exemplified here by increased
delta AUC at 800–900 ms after stimulus period in Pz.
N200 amplitudes during visual tasks have been interpreted as
reflecting attentional engagement with visual stimuli, such that
more positive N200 amplitudes reflect preferential processing or
increased attentional engagement with emotional versus neutral
visual stimuli (Carretie et al., 2004; Feng et al., 2014). S-ketamine
may have blocked the expectation-induced decrease on delta
AUC of this component as well. This effect can be seen also
in absolute mean amplitude differences in N200 component
at Pz (Table 2).
In the opposite way of we expected, the difference between
ERPs elicited by target and standard words was increased in
S-ketamine when compared to placebo group. This finding
could be explained by the methodological fact that words were
randomized in blocks of 5 with a 4:1 rate between targets
and standards, which created a non-completely random stimuli
order. Behavioral data shows that target words were far more
negative (83% vs. 25%; p < 0.01) than standard words (Table 2).
Thus, these small sized blocks may have induced subjects to
predict a relatively regular pattern of appearance of pain-related
(intrinsically negative) words. Indeed, we found difference in
early processing of stimuli, as can be seen in increased delta
AUC of 70–170 ms after stimulus in Cz. This suggest that
interpretation was modulated by expectation, once semantic
processing typically occurs in a later timeframe (usually about
400 ms after stimulus).
When discussing behavioral data, the present findings
demonstrate that S-ketamine infusion led individuals to perceive
pain-related words as less negative (Table 2), which is consistent
with the previous interpretation. We should consider here that
target words were pain-related and, therefore, had intrinsic
negative emotional valence as discussed above, while standard
words were diverse regarding their valences. As expected,
ratings as “positive” semantic valence in pain-related words
were very low and did not change significantly. However,
S-ketamine significantly reduced the negative valence ratings of
target words (pain-related) while increased their classification as
“neutral” with a trend for a difference with statistical significance
(P = 0.052). This fact reinforces the hypothesis that ketamine
impairs the ability to differentiate sensorial stimuli. Furthermore,
the notion that NMDA-receptor antagonism is not only relevant
to cognitive, but also to emotional processing is supported by the
rapid antidepressant effect of ketamine in otherwise treatment-
resistant major depression patients (Zarate et al., 2006).
We did not find a difference between groups in reaction
times. According to previous studies (Ohman et al., 2001), stimuli
with emotional content seem to attract and withhold attention
longer when compared to non-emotional stimuli. Even though
it is not clear whether this effect is driven by the valence
(Estes and Verges, 2008) or the arousal dimension (Schimmack
and Derryberry, 2005; Vogt et al., 2008), it is assumed that
the longer attentional engagement toward incoming emotional
information leads to a slower response in co-occurring non-
emotional tasks (Lang et al., 1993). As in the current study
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subjects were not instructed to classify words as fast as they could,
we did not expect RTs to be different in this context. However,
it is possible that the increase of standard word neutral ratings
seen in placebo group (at the expense of a reduction in positive
and negative ratings) are consequence of selective attentional
allocation to emotional words, which could lead to a decreased
discriminative performance.
However, in the interpretation of these results, it should be
noted that in our protocol the standard words presented in the
task didn’t have a predetermined valence, as occurred in other
studies (Dillmann et al., 2000; Imbir et al., 2016). For instance,
the word “dog” was perceived both as “positive,” “negative,” or
“neutral” according to the interpretation of each subject. This
should be seen as an advantage, as subjective interpretation can
significantly vary to the same word among individuals.
Overall, the data suggest a role of S-ketamine (and the
NMDA-glutamatergic receptor systems) in the modulation of
the perceived emotional valence of the stimuli. However, a
combination of ketamine dose and methodological differences
among reports may have contributed to the divergence of our
results, at least in part, with previous published data.
Limitations
This study was intended to be primarily exploratory and,
therefore have several limitations. We studied the effects of a
single dose of S-ketamine only, then it is not possible to determine
from the current data if the NMDA glutamatergic effects on the
P300 complex vary in a dose dependent manner. The oddball task
we used in this report was innovative but has limitations in terms
of the behavioral and neurophysiological dependent variables
generated. The effects of S-ketamine on the ERP correlates of
semantic affective processing should be studied in the future with
less complex but more behaviorally rich paradigms. Finally, some
behavioral differences were marginally significant and should be
interpreted cautiously.
CONCLUSION
This study explored the effects of S-ketamine on the affective
aspect of interpretation of stimuli using ERPs. We found
evidence of change in interpretation of pain-related words both
on neurophysiological and behavioral outcomes. S-ketamine
induced a state of emotional and discrimination blunting, leading
to increased delta AUCs relative do N200 and P300 when
compared to placebo.
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